[Clinical effect of terodiline hydrochloride on nervous pollakisuria or irritative bladder].
The clinical effect of terodiline hydrochloride (TD-758) was studied in 95 patients with nervous pollakisuria or irritative bladder. TD-758 was given per os randomly at a dose of 24 mg or 12 mg once a day for 4 weeks. The symptoms such as urinary frequency, urinary incontinence and sense of residual urine were improved in 74% of the patients taking 24 mg, and in 51% of the patients taking 12 mg. The difference was statistically significant. Side effects such as dry mouth, constipation and heart burn were observed in 15% of the patients in each group and were not serious. The results of this study indicate that TD-758 is useful for these patients and its optimal dosage is 24 mg once a day.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002082:Butylamines / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D011141:Polyuria / Q000188:drug therapy*; D001745:Urinary Bladder Diseases / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
D002082:Butylamines; D002121:Calcium Channel Blockers; C010637:terodiline